Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)

  • STATUS
    Not Recruiting
  • End date
    Mar 17, 2022
  • participants needed
    4500
  • sponsor
    GlaxoSmithKline
Updated on 23 May 2021
Investigator
US GSK Clinical Trials Call Center
Primary Contact
GSK Investigational Site (1.0 mi away) Contact
+505 other location
iron
erythropoietin
dialysis
renal disease
darbepoetin alfa
iron therapy
daprodustat
anemia studies

Summary

The purpose of this multi-center event-driven study in non-dialysis (ND) participants with anemia associated with chronic kidney disease (CKD) is to evaluate the safety and efficacy of daprodustat compared to darbepoetin alfa.

Details
Condition Anemia, Anemia; Non-Hodgkin’s Lymphoma
Treatment Placebo, darbepoetin alfa, Daprodustat, Iron Therapy
Clinical Study IdentifierNCT02876835
SponsorGlaxoSmithKline
Last Modified on23 May 2021

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note